BI 1358894 DDI with Bupropion in Healthy Volunteers

Phase 1, open-label, single-arm trial of bi 1358894 in major depressive disorder (MDD), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Bupropion in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point up to 120 hours and Maximum Measured Concentration of Bupropion in Plasma up to 120 hours. Started Jun 2021; status: completed.